Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2025-05-18 Report Publication Anno…
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to stock exchanges submitting copies of published audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2025. It references the approval of these results by the Board of Directors on May 16, 2025, and includes newspaper publications with QR codes linking to the full financial results. The document itself does not contain the financial results or detailed financial data but rather announces the publication and availability of these results. The document length is short (1554 characters), and it serves as a notification or announcement rather than the full report. According to the 'Menu vs Meal' rule, this is a report publication announcement rather than the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2025-05-18 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated May 16, 2025, from Jubilant Pharmova Limited announcing the financial results for the quarter and financial year ended March 31, 2025. It includes detailed financial data such as revenue, EBITDA, PAT, segmental business performance, and strategic outlook. The document also contains a Chairman's message discussing the company's Vision 2030 and business growth plans. The length is substantial (15,000 characters), and it contains actual financial statements and substantive analysis, not just a summary or announcement of a report. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights. It is not a full Annual Report (10-K) or Interim Report (IR) because it is a press release focused on earnings results and operational performance for the quarter and fiscal year. Therefore, the appropriate classification is Earnings Release (ER). FY 2025
2025-05-16 English
Dividend
Annual Report Classification · 95% confidence The document is a detailed announcement from Jubilant Pharmova Limited dated May 16, 2025, addressed to stock exchanges and shareholders. It reports the outcome of a Board Meeting where the audited financial results for the quarter and financial year ended March 31, 2025, were approved. It includes the auditor's report with an unmodified opinion, a declaration from the CFO confirming the audit opinion, and detailed auditor's responsibilities and opinions. The document contains substantive financial data, auditor's detailed report, and management declarations, indicating it is the actual audited financial results report rather than a mere announcement or certification. The presence of full auditor's report and financial results for the fiscal year confirms this is the Annual Report filing. Therefore, the document should be classified as an Annual Report (10-K).
2025-05-16 English
Record Date
Annual Report Classification · 95% confidence The document is a detailed announcement from Jubilant Pharmova Limited dated May 16, 2025, reporting the outcome of a Board Meeting where the audited financial results for the quarter and financial year ended March 31, 2025, were approved. It includes the auditor's report with an unmodified opinion, a declaration from the CFO and Whole-Time Director confirming the auditor's opinion, and detailed auditor's responsibilities and opinion sections. The document contains substantive financial data, auditor's detailed report, and management declarations, indicating it is the actual audited financial results report rather than a mere announcement or certification. The presence of comprehensive audit details and financial results for the full fiscal year aligns with the characteristics of an Annual Report (10-K equivalent). Therefore, the document should be classified as an Annual Report (10-K).
2025-05-16 English
Appointment
Board/Management Information Classification · 95% confidence The document is a formal announcement dated May 16, 2025, addressed to stock exchanges regarding the outcome of a Board Meeting. It specifically reports the appointment of a Secretarial Audit firm for a future period, subject to shareholder approval at the upcoming AGM. The document references Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, which governs disclosures related to board decisions and corporate governance. The content is focused on informing stakeholders about a board decision rather than providing detailed financial data, audit results, or full reports. The document length is 3376 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Board/Management Information (MANG), as it announces a change in the company's board-related appointments.
2025-05-16 English
Outcome of Board Meeting
Annual Report Classification · 95% confidence The document is a detailed announcement from Jubilant Pharmova Limited dated May 16, 2025, reporting the outcome of a Board Meeting where the audited financial results for the quarter and financial year ended March 31, 2025, were approved. It includes the auditor's report with an unmodified opinion, a declaration from the CFO and Whole-Time Director confirming the auditor's opinion, and detailed auditor's responsibilities and opinion sections. The document contains substantive financial data, auditor's detailed report, and management declarations, indicating it is the actual audited financial results report rather than a mere announcement or certification. The presence of comprehensive audit details and financial results for the full fiscal year confirms this is the Annual Report filing. Therefore, the document fits the definition of an Annual Report (10-K).
2025-05-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.